UBS raised the firm’s price target on Cencora (COR) to $335 from $298 and keeps a Buy rating on the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora’s Strategic Growth and Industry Positioning Justify Buy Rating
- Cencora price target raised to $288 from $263 at Morgan Stanley
- Cardinal Health price target raised to $155 from $150 at BofA
- Cencora price target raised to $285 from $270 at BofA
- McKesson price target raised to $755 from $665 at BofA